Proposed new legislation in France

 

TIDMCRYO 
 
 
Cryo-Save Group NV 
10 December 2009 
 
? 
10 December 2009 
 
 
Cryo-Save Group N.V. 
 
 
Cryo-Save welcomes new proposed French Law supporting Cord Blood banking 
 
 
Cryo-Save Group N.V. (AIM/Euronext: CRYO, "Cryo-Save" or "the Group"), Europe's 
leading stem cell bank, notes and welcomes the announcement of proposed new 
legislation in France supporting the collection and preservation of umbilical 
cord blood stem cells. 
 
 
The proposed legislation, which was announced by Deputy Damien Meslot at a press 
conference in Paris yesterday, along with Nico Forraz, Managing Director of 
Cryo-Save France, includes recommendations that: 
 
(I) During prenatal exams, pregnant women should be informed about cord blood 
stem cells and their therapeutic indications, as well as about the possibility 
of donating these stem cells for therapeutic or scientific use, or to store the 
stem cells for a potential autologous or allogenic therapeutic use. 
(II) All mothers should be allowed to have their umbilical cord blood stem cells 
collected, processed and stored by public or private entities for scientific use 
or for potential autologous or allogenic therapeutic use. 
 
Marc Waeterschoot, Chief Executive, commented: 
 
 
"It is paramount to inform expecting women and parents on the therapeutic 
benefits of umbilical cord and cord blood derived stem cells. Already all over 
Europe, parents are offered options to privately store umbilical cord and cord 
blood stem cell. 
 
 "This new proposed legislation will be very important in helping  to create 
awareness in France of  cord blood banking and will significantly contribute to 
the development of our operations in the Country which, with 850,000 births per 
year, has the potential to become the largest cord blood market in Europe." 
 
 
+-------------------------------------+----------------------------------+ 
| For further details:                |                                  | 
+-------------------------------------+----------------------------------+ 
| Cryo-Save Group                     |             + 31 (0) 575 548 998 | 
+-------------------------------------+----------------------------------+ 
| Marc Waeterschoot, Chief Executive  |                                  | 
| Arnoud van Tulder, Chief Financial  |                                  | 
| Officer                             |                                  | 
+-------------------------------------+----------------------------------+ 
|                                     |                                  | 
+-------------------------------------+----------------------------------+ 
| Daniel Stewart & Company plc        |            + 44 (0) 20 7776 6550 | 
+-------------------------------------+----------------------------------+ 
| Simon Leathers/Tessa Smith          |                                  | 
+-------------------------------------+----------------------------------+ 
|                                     |                                  | 
+-------------------------------------+----------------------------------+ 
| College Hill                        |           + 44 (0) 20 7457 2020  | 
+-------------------------------------+----------------------------------+ 
| Adrian Duffield/Rozi Morris         |                                  | 
+-------------------------------------+----------------------------------+ 
 
 
About Cryo-Save 
 
 
With more than 120,000 samples saved, Cryo-Save is the leading stem cell bank in 
Europe and one of the fastest growing in the world. Driven by its international 
business strategy, Cryo-Save is now represented in 38 countries on three 
continents and has state-of-the-art processing facilities in Belgium, Germany, 
Dubai, India and France (under construction). 
 
 
Cryo-Save sets the highest quality standards in stem cell storage, as it aims to 
make an important contribution to conquer possible life-threatening diseases in 
the future. As a service to the public, Cryo-Save offers a Cost-free Family 
Donation Programme, free of charge, to families wishing to store their newborn's 
umbilical cord blood stem cells for a family member diagnosed with a 
life-threatening disease treatable by stem cells. The company is committed to 
further improve stem cell cryopreservation techniques, by participating in 
European Commission funded projects, in Universities and Hospitals. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRACKCKNABDDABK